Contemporary management of pericardial effusion.


Journal

Panminerva medica
ISSN: 1827-1898
Titre abrégé: Panminerva Med
Pays: Italy
ID NLM: 0421110

Informations de publication

Date de publication:
Sep 2021
Historique:
pubmed: 5 1 2021
medline: 23 3 2022
entrez: 4 1 2021
Statut: ppublish

Résumé

Pericardial effusion is a relatively common clinical condition with a variety of clinical manifestations ranging from incidentally discovered asymptomatic cases to life-threatening cardiac tamponade. The etiology encompasses idiopathic cases and forms secondary to different conditions, including autoimmune diseases, malignancies, metabolic disorders, etc. While medical therapy should be offered to patients with elevation of inflammatory markers, in specific forms treatment should be appropriate to the underlying disorder. In cases with hemodynamic compromise pericardial drainage either with pericardiocentesis or pericardial "window" is indicated for therapeutic and diagnostic purposes. In the remainder, factors like comorbidities, size and location of the pericardial effusion will influence the clinical decision making. In asymptomatic or minimally symptomatic chronic large idiopathic pericardial effusions, according to recent evidence, a conservative approach with watchful waiting seems the most reasonable option. The prognosis of pericardial effusions largely depends on the underlying etiologies. Metastatic spread to the pericardium has an ominous prognosis whereas large to moderate effusions have been often associated with known or newly discovered specific underlying causes. Chronic small idiopathic effusions have an excellent prognosis and do not require specific monitoring. Large chronic idiopathic effusions in clinically stable patients require a 3 to 6-month assessment ideally in a specialized unit.

Identifiants

pubmed: 33393752
pii: S0031-0808.20.04197-X
doi: 10.23736/S0031-0808.20.04197-X
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

288-300

Auteurs

George Lazaros (G)

School of Medicine, First Cardiology Clinic, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece - glaz35@hotmail.com.

Charalambos Vlachopoulos (C)

School of Medicine, First Cardiology Clinic, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Emilia Lazarou (E)

School of Medicine, First Cardiology Clinic, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Dimitris Tousoulis (D)

School of Medicine, First Cardiology Clinic, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Constantinos Tsioufis (C)

School of Medicine, First Cardiology Clinic, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH